Publications

• Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.

  (Langley RGB, Reich K, Strand V, Feldman SR, Paul C, Gordon K, Warren RB, Toth D, Nikaï E, Zhu B, Goldblum O, Edson-Heredia E, Carlier H, Burge R, Lin CY, Hollister K, Augustin M.) Qual Life Res. 2020 Feb;29(2):369-380 PMID: 31655974 10/28/2019

• Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.

  (Lebwohl MG, Gordon KB, Gallo G, Zhang L, Paul C.) J Eur Acad Dermatol Venereol. 2020 Feb;34(2):301-309 PMID: 31479549 09/04/2019

• Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry.

  (Callis Duffin K, Mason MA, Gordon K, Harrison RW, Crabtree MM, Guana A, Germino R, Lebwohl M.) Dermatology. 2020 Jan 21:1-10 PMID: 31962340 01/22/2020

• Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis.

  (Burmester GR, Gordon KB, Rosenbaum JT, Arikan D, Lau WL, Li P, Faccin F, Panaccione R.) Adv Ther. 2020 Jan;37(1):364-380 PMID: 31748904 PMCID: PMC6979455 11/22/2019

• Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.

  (Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Elmets CA.) J Am Acad Dermatol. 2020 Jan;82(1):161-201 PMID: 31703821 11/11/2019

• Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2.

  (Reich K, Song M, Li S, Jiang J, Youn SW, Tsai TF, Choe YB, Huang YH, Gordon KB.) J Dermatol. 2019 Dec;46(12):1141-1152 PMID: 31631377 10/22/2019

• Risankizumab in moderate-to-severe plaque psoriasis.

  (Serrano L, Maloney V, Gordon KB.) Immunotherapy. 2019 11;11(16):1357-1370 PMID: 31578912 10/04/2019

• Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.

  (Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, Armstrong AW, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Leonardi CL, Lichten J, Mehta NN, Paller AS, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A.) J Am Acad Dermatol. 2019 Sep;81(3):775-804 PMID: 31351884 07/29/2019

• Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.

  (Elewski B, Menter A, Crowley J, Tyring S, Zhao Y, Lowry S, Rozzo S, Mendelsohn AM, Parno J, Gordon K.) J Dermatolog Treat. 2019 Jul 22:1-6 PMID: 31268369 07/04/2019

• A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.

  (Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J, IXORA-R Study Group.) Br J Dermatol. 2019 Dec 30 PMID: 31887225 12/31/2019

• Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.

  (Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, Li S, Shen YK, Han C, Kimball AB, Armstrong AW, Foley P, Blauvelt A.) J Am Acad Dermatol. 2019 Dec 04 PMID: 31809827 12/07/2019

• Defining drug-free remission of skin disease in patients with plaque psoriasis.

  (Armstrong AW, Blauvelt A, Crowley JJ, Gordon KB, Krueger GG, Krueger JG, Sobell JM, Strober BE, Srivastava B, Menter A.) Br J Dermatol. 2019 Nov 09 PMID: 31705649 11/11/2019